Amneal Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amneal Pharmaceuticals (AMRX).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$18Upside to Avg. PT-18.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$22→$24
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$27
Sep 17, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$16→$20
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$23
Aug 26, 2026	JP Morgan	Chris Schott	Reinstates	Overweight	$22
Aug 3, 2026	UBS	Ashwani Verma	PT Raise	Buy	$23→$25
Jul 15, 2026	UBS	Ashwani Verma	PT Raise	Buy	$19→$23
May 20, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$15→$16
Apr 17, 2026	UBS	Ashwani Verma	Initiate	Buy	$19
Mar 2, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$15→$17
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$15
Oct 31, 2025	Piper Sandler	David Amsellem	PT Raise	Overweight	$11→$13
Sep 16, 2025	JP Morgan	Chris Schott	PT Raise	Overweight	$12→$14
Mar 3, 2025	Barclays	Balaji Prasad	PT Raise	Overweight	$10→$11
Feb 24, 2025	JP Morgan	Chris Schott	Upgrade	Neutral→Overweight	$9→$12
Nov 11, 2024	Piper Sandler	David Amsellem	PT Raise	Overweight	$9→$11
Oct 2, 2024	Truist Securities	Les Sulewski	PT Raise	Buy	$10→$12
Sep 6, 2024	JP Morgan	Chris Schott	Upgrade	Underweight→Neutral	$9
Aug 13, 2024	Barclays	Balaji Prasad	PT Raise	Overweight	$8→$10
Aug 12, 2024	Truist Securities	Les Sulewski	PT Raise	Buy	$9→$10

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.

Benzinga Newsdesk

PRO
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.

Benzinga Newsdesk

Amneal Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Amneal Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

PRO
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

PRO
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

PRO
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

People Also Watch

People Also Watch

Amneal Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Amneal Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

PROOppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

PROBarclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

PROLeerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

PROJP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

PROUBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

PRO
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

PRO
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

PRO
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25